ASH 2024 – Jennifer A. Woyach
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationJennifer A. Woyach summarizes the current knowledge on BTK mutations and their clinical relevance in patients with CLL receiving BTK inhibitor therapy. She explains how patients fare after discontinuing BTK inhibitors due to toxicity and highlights the potential of next-generation BTK inhibitors, such as zanubrutinib, in combination with BCL-2 inhibitors like sonrotoclax for treatment-naïve CLL.